Among the most promising therapeutic options for individuals with coronavirus disease 2019 (COVID-19) are monoclonal antibodies (mAbs). In this study, Jones et al . identified, characterized, and tested one such mAb, LY-CoV555, in vitro and in vivo. They found that LY-CoV555 bound to the severe acute respiratory distress syndrome coronavirus-2 (SARS-CoV-2) spike protein and prevented its interaction with angiotensin-converting enzyme 2. Prophylactic treatment with LY-CoV555 protected the upper and lower respiratory tracts of nonhuman primates from becoming infected with SARS-CoV-2. Together, these data support the clinical use of LY-CoV555 for treating patients with COVID-19.
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health threat for which preventive and therapeutic agents are urgently needed. Neutralizing antibodies are a key class of therapeutics that may bridge widespread vaccination campaigns and offer a treatment solution in populations less res
n 111) and contacts (
K and
L) The normalized AUC of anti-RBD IgA (K) or IgG (L) ELISA for patients with gastrointestinal (GI) symptoms (
n 32) and without GI symptoms (
n 117) was plotted. The
r and
P values for the correlations in (C) to (G) were determined by two-tailed Spearman’s correlations. For (H) to (L), horizontal bars indicate median values. Statistical significance was determined using a two-tailed Mann-Whitney
U test.
P 0.005) and severity of symptoms (
P 0.0001) but not timing of sample collection relative to onset (
P 0.69) or age (
P 0.22) (Fig. 1, C to F). Concentrations of anti-RBD IgA antibodies correlated strongly with anti-RBD IgG concentrations (
Studies reveal potential weaknesses in SARS-CoV-2 infection — Agenparl agenparl.eu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from agenparl.eu Daily Mail and Mail on Sunday newspapers.